Background: Pentraxins are generally considered acute phase proteins. Pentraxin 3 (PTX3), a long pentraxin, has been identified as an inflammatory biomarker, and its blood levels increase rapidly and dramatically in inflammatory conditions. Elevated plasma PTX3 levels were reported in patients with high systolic and diastolic blood pressures, and PTX3 can be an early marker of arteriosclerotic vascular damage. Carotid artery intima-media thickness (cIMT) is a well-established surrogate marker for subclinical atherosclerosis. However, the association between biomarkers of systemic inflammation and atherosclerosis progression in carotid artery is not well established. Aim of Study: Was to evaluate the value of plasma PTX3 level as a predictor for asymptomatic preclinical hypertensive-related atherosclerotic vascular disease. Subjects and Methods: 75 patients with primary hypertension who had no history or manifestations suggesting atherosclerotic vascular disease and 15 healthy subjects (control group) were included. Full history taking and thorough medical examination were done. Patients' weight, height, BMI, and blood pressure were assessed. Laboratory investigations (urine analysis, UACR, CBC, ESR, CRP, liver enzymes, urea, creatinine, blood sugar levels, HbA1c, uric acid, LDL cholesterol, HDL cholesterol, triglyceride, and PTX3 levels), ECG, echocardiography, and carotid ultrasonography (for measuring cIMT) were performed for all patients. Results: The mean age of patients was 54.7±9.3 years (range, 38-73 years). Asymptomatic preclinical atherosclerotic vascular disease, as reflected by cIMT > 0.1cm, was reported in 39 patients (52%). Hypertensive patients with LDL cholesterol ≥ 100mg/dL or with HDL cholesterol < 50mg/dL for males and < 40mg/dL for females had significantly higher plasma PTX3 levels. Higher degrees of UACR and albuminuria were associated with significantly elevated plasma PTX3 levels. Plasma PTX3 levels were significantly higher in hypertensive patients with preclinical atherosclerotic vascular disease,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.